Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Voigt who wrote (1348)	5/19/1998 3:46:00 PM
From: Greg Kevorkian	Read Replies (1) \| Respond to of 1533

Questions to Alfacell 1 Did you present at ASCO 2 If not, Why 3 If yes, why no big noise about Onconase. Why do I ask these questions. Email FJ Abella Westergaard Online Westergaard Broadcasting Network Westergaard Year 2000 Tuesday May 19, 1998 We have seen the mainstream press go wild over cancer in the past several weeks. Two examples - the New York Times reported one month after the news elease that Entremed (Nsdq:ENMD) had cured cancer in mice. Last night we were treated by CNN talking about the slightest increases (undetectable ) in the effectiveness of taxol for early stage breast cancer over conventional chemotherapy. These are what the press consider to be breakthroughs in cancer research? I consider the news SuperGen released from ASCO to be among the most significant to be forthcoming from the meeting (right up there with Genentech's Phase II B-cell Non Hodgkin's lymphoma data). Consider RFS2000, SuperGen's drug for pancreatic cancer. Data showed that among 53 patients, 32% were responders, 32% were stable and 26% were non- responders following treatment with RFS 2000. Responses were evaluated by improvement in CT scan, tumor markers and clinical symptomatology. Median survival to date is 9.1 months among responders, and 8.8 months among stable patients. Standard treatment for this condition includes Eli Lilly's (NYSE:LLY) Gemzar. The prognosis of a patient with locally advanced or metastatic breast cancer is 3-4 months, even with treatment with Gemzar. That SUPG is finding that 64% of the patients are surviving out to nine months IS ONE OF THE MOST SIGNIFICANT ANNOUNCEMENTS TO BE MADE AT ASCO. By the way, sales of Gemzar in 1996 and 1997 were $62mm and $175mm respectively. If FDA is as compelled by the data as we are, SUPG may be marketing RFS2000 for pancreatic cancer within 12-18 months. I would really like some answers to these question and a response to this latest announcement.